We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > darolutamide

News List

Darolutamide NDA to treat non-metastatic castration-resistant prostate cancer europeanpharmaceuticalreview
April 12, 2019
A New Drug Application has been made to the US Food and Drug Administration for the drug darolutamide to treat non-metastatic prostate cancer…
Bayer files prostate cancer drug darolutamide in Japan pharmaphorum
March 07, 2019
Bayer has filed its prostate cancer drug darolutamide with Japanese regulators, in an attempt to ratchet up the pressure on rivals Johnson & Johnson and Pfizer/Astellas.
Bayer plans filings for prostate cancer drug darolutamide pharmaphorum
December 20, 2018
Bayer is planning regulatory filings of darolutamide in prostate cancer following phase III trial results showing it helped prevent the disease from spreading, in a niche where Pfizer and Johnson & Johnson have already gained a foothold.